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This special issue wants to contribute to a better understand-
ing of cardiac involvement in sepsis. Sepsis is a complex
syndrome that has recently been defined as “life-threatening
organ dysfunction due to a dysregulated host response to
infection” [1, 2]. It should be considered amajor public health
problem since it affects millions of people worldwide each
year, and it accounts for most deaths in critically ill patients.
Thepresence ofmyocardial dysfunction in sepsis is associated
with higher mortality.
A great attention has been dedicated to improving our
knowledge and understanding of the intricate mechanisms
underlying sepsis. However, data from the literature suggest
the need to implement strategies to reliably measure sepsis
morbidity and mortality. In fact, methods based on analyses
of insurance claimdata using sepsis-specific codes or separate
codes for infection and organ dysfunction are unreliable in
informing or measuring the effects of policy changes [3,
4], and the postmortem diagnosis of sepsis is often elusive
since postmortem investigations lack certain pathognomonic
macroscopic and histopathological findings [5, 6]. From
a morphological and diagnostic point of view, the term
“septic disease” has been created to describe the cardiac
involvement in the syndrome. However, this definition,
rather than describing a morphological finding, was instead
referred to the clinical setting. Although in recent years the
concept of septic cardiomyopathy has evolved and it involves
pathological alterations of myocardial cells in response to the
multiplicity of acting mechanism of damage, the importance
of structural changes during sepsis is often overlooked. In
patients with sepsis, death is usually the result of a progressive
multiorgan dysfunction, overlooking the primary infection
through the hyperinflammation. The cardiac involvement as
fundamental part of septicmultiorgan dysfunction syndrome
has been discussed for a long time.
C. Pomara et al. explored the state of current knowledge
on the molecular and biohumoral mechanisms of sepsis and
correlate them with our ability at postmortem diagnosis. The
authors highlight that a complete methodological approach,
integrating clinical data by means of autopsy and histological
and laboratory findings aiming to identify and demonstrate
the host response to infectious insult, is mandatory. Such
an approach would be likely to produce an accurate objec-
tive surveillance of deaths due to sepsis and improve our
knowledge of the clinical-pathological correlation in sepsis,
thus contributing to the evaluation of the effectiveness of
therapies.
Sepsis is characterized by symptoms and manifestations
of organ dysfunction that may lead to fatal outcome.Myocar-
dial dysfunction in sepsis is mediated by a complex interplay
among several factors that still remains incompletely under-
stood [7]. Circulatory compromise and microcirculatory
alterationsmay, in part, explain cardiac impairment in sepsis.
However, in recent years increasing attention has been paid to
the study of other possible pathways of myocardial dysfunc-
tion in sepsis. The effects of the host’s immune-inflammatory
response with particular focus on depressant molecules,
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complement molecules, cellular adhesion molecules, and
altered intracellular energetic, dysregulated intracellular cal-
cium fluxes have been called upon in the pathophysiology
of myocardial depression in sepsis. Oxidative-nitrosative
stress may contribute to cardiac dysfunction in sepsis, and
mitochondria are one of the major sites for generation of
reactive oxygen species and reactive nitrosative species as a
detrimental side product of oxidative energy metabolism [8].
M. Neri et al. reviewed the evidence for a role of oxidative-
nitrosative stress unbalance and mitochondria dysfunction
in myocardial depression in sepsis. NADPH oxidase-derived
reactive oxygen species, the role of mitochondria, and finally
the involvement of nitric oxide and peroxynitrite as critical
factors in mediating myocardial dysfunction in sepsis are
discussed.
Measurement of biomarkers is a potential approach to
early prediction of the risk of mortality in patients with
sepsis. Over the years, a great amount of molecules has
been proposed as potential biological markers [9]. However,
only 20% of these biomarkers have been assessed specifically
in appropriate studies for use in the diagnosis of sepsis
[10]. To date an ideal clinical and postmortem marker of
sepsis does not exist. Proadrenomedullin and copeptin are
peptides cosynthesized together with adrenomedullin and
vasopressin in endothelial cells and pituitary gland, respec-
tively. These peptides are increased during sepsis. They have
vasoactive, immune modulating, and metabolic properties.
It was recently reported that adrenomedullin plays a central
role in initiating the hyperdynamic response during the early
stages of sepsis and was a useful predictor for development
of severe sepsis and septic shock [11, 12]. W. Hu et al.
discuss the prognostic value of adrenomedullin and atrial and
brain natriuretic peptides in uroseptic patients induced by
ureteroscopy. In their research article the authors suggest that
the prognostic value of adrenomedullin is superior to atrial
and brain natriuretic peptides and that all thesemolecules are
robust independent predictors of in-hospital death in urosep-
tic patients. They conclude that adrenomedullin and atrial
and brain natriuretic peptides may participate in initiating
the hyperdynamic response during the early stages of sepsis
in uroseptic patients and that these biomarkers could be
considered strong predictors of adverse outcome in patients
with urosepsis.
Finally, two articles of the special issue discuss the
potential link existing between inflammatory status and
cardiometabolic disorders. It has been well established that
inflammation is also able to affect lipoprotein metabolism.
However, the precise mechanisms pathophysiologically link-
ing metabolic dysfunction and inflammation are still under
investigation. The biological basis for these associations
includes both systemic and local tissue effects.
Metabolic Syndrome (MetS) is a constellation of dis-
eases that include obesity, diabetes, hypertension, dys-
lipidemia, hypertriglyceridemia, and hypercholesterolemia.
These metabolic derangements trigger a persistent inflam-
matory cascade, whit recruitment of immune cells to the
site of injury, and subsequent expression of cytokines
and chemokines that amplify the inflammatory response
[13]. A common link between inflammation and MetS
has been suggested. In cardiometabolic disorders a high
serum lipopolysaccharides activity has been demonstrated,
thus suggesting a potential role of bacterial infections and
immune response in their etiology [14]. One article dis-
cussed the serum adiponectin levels and the homeostasis
model assessment-insulin resistance (HOMA-IR) that are
reportedly associated with MetS. Y.-S. Ding et al. concluded
that the adiponectin to HOMA-IR ratio (A/H) may be a
better diagnostic marker for MetS than either HOMA-IR
or adiponectin alone, and it may serve as an important
biomarker to determine an increased risk for MetS in healthy
middle-aged population. Y. Zhang et al. investigated the rela-
tionship between inflammatory markers and the atherogenic
lipoprotein subfractions, and they hypothesized presence of
heterogeneity in the relationship of systemic inflammatory
markers with atherogenic lipoprotein subfractions, which
would aid our understanding of their interplay in the patho-
genesis of atherosclerotic disease.
This special issue is dedicated to the cardiovascular
involvement in sepsis. The high mortality associated with
sepsis makes a thorough knowledge of its underlying mech-
anisms and its pathophysiological connections with the
cardiometabolic disorders important.
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